哌拉西林/舒巴坦对临床分离菌的体外抗菌作用  

In vitro inhibitory activity of piperacillin/sulbactam against clinical isolates

作　　者：宣天芝[1] 陶风荣[1] 许宏涛[1] 张秀珍[1] 

机构地区：[1]卫生部北京医院,北京100730

出　　处：《中国抗生素杂志》2001年第6期454-456,463,共4页Chinese Journal of Antibiotics

摘　　要：目的　对哌拉西林 /舒巴坦进行体外抗菌活性研究。方法　采用琼脂二倍稀释法测定最低抑菌浓度 ,采用肉汤稀释法测定最低杀菌浓度 ,并对其影响因素进行测定。结果　本品对肠杆菌科细菌、非发酵菌、葡萄球菌、粪肠球菌抗菌活性均低于亚胺培南 ,对不产酶流感嗜血杆菌和粘膜莫拉氏菌抗菌活性高于亚胺培南 2～ 16倍。对肺炎链球菌和嗜麦芽黄单胞菌的抗菌活性同本次所研究的所有对照药。对临床常见 5种致病菌 (铜绿假单胞菌、大肠埃希氏菌、肺炎克雷伯氏菌、金葡球菌和粪肠球菌 )的 MIC和 MBC非常接近 ,差异在 0～ 2之间 。In vitro inhibitory activity of piperacillin/sulbactam has been studied. The MICs and MBCs tests were carried out using the agar double- and broth-dilutions methods respectively, and the affecting factors were also determined. Results showed that the inhibitory activities of piperacillin/sulbactam against the Enterobacteraceae, non-fermenters, Staphylococcus spp. and Enterobacter cloacae were lower than imipenem. The MBCs of piperacillin/sulbactam against non-enzyme producer Haemophilus spp. and Moraxella catarrhalis were 2~16 folds higher than that of imipenem; as for against Streptococcus pneumoniae and Xanthomonas maltophilia were the same as other antibiotics in the study. The MICs of piperacillin/sulbactam against the five common pathogens, (e.g.Pseudomonas aeruginosa, E.coli, Klebsiella pneumoniae, Staphylococcus aureus and Enterobacter faecalis), were closed to the MBCs, which differed in the range from 0~2, and therefore, it could be considered as a bactericidal antibiotic.

关 键 词：哌拉西林/舒巴坦 体外抗菌活性 临床分离菌 

分 类 号：R978.11[医药卫生—药品] R969.4[医药卫生—药学]